This event is about the developments made in the field of COPD.
COPD its self-causes 6% of the world’s morbidity. It is predicted that there will be a 30% > increase in the number of cases in the next 10 years.

The disease is chronic and is characterised by a progressive worsening in condition through periods of exacerbation caused by infection and progressive worsening through opportunistic infections.
The disease, though non curable, can be tamed through a range of management mechanisms, such as preventing the development of exacerbations through flu and pneumonia vaccines and early diagnosis and treatment of exacerbations through rapid deployment of antibiotics. Lung function can also be increased and exacerbations reduced through the use of bronchodilators such as corticosteroids and anticholinergic drugs.


Now in its 7th year, COPD 2015 will gather a global audience of respiratory experts and scientific pioneers to discuss the latest developments in combinational therapies, new drugs and personalised treatment as well as the challenges of clinical trials. Join us as we ask questions such as: How does one reliably recruit and run clinical trials in a disease that branches to such extremes? What is the correct phenotype to measure in the disease? With the majority of COPD patients on varying courses of polypharmacy due to a range of different debilitating diseases alongside COPD – how can one find a clean patient? Plus much more!

 Our understanding of the pathophysiology in COPD has increased dramatically thanks to developments in the area of network biology. By understanding the complicated mechanisms by which different aspects of the disease interact it is possible to intervene with crucial nodes progressing the disease. Discussions will be opened on the various models of network biology and biomarkers of the disease to gain a greater understanding of this multifaceted disease.

We look forwards to welcoming you to the 7th Annual COPD Conference 2015 taking place in central London on the 19th-20th October 2015.



• Discuss the advantages and disadvantages of combinational therapeutics
• Gain insight into formulation developments and the manufacturing of dry powder inhalation products
• Evaluate COPD and comorbidities
• Review the challenges in clinical trial designs and in drug development
• Learn about "first in class" inhaled drugs for the treatment of COPD and cystic fibrosis
• Ascertain the ACOS Definition and characteristics of a grey-zone syndrome, excluded from current asthma and COPD trials
• Explore recent advances made in COPD biomarkers
• Study the role of lymphoid follicles in COPD Novel delivery and formulation methods
• Analyse airway disease endotyping for personalized therapeutics


The event is being run now thanks to developments in the field of personalized medicines. The changes include the development of rapid PCR mechanisms and various transcriptomic analysis mechanisms.
The era of personalized medicines has made large changes to treatment strategy opportunities in COPD. This is primarily due to the diseases large range of phenotypes associated with its manifestation. This brings up the problem of clinical trials. How does one reliably recruit and run clinical trials in a disease that branches to such extremes. This will be discusses at the conferece this year along with COPD co morbidities and Recent advances in COPD treatment options.

Chief Executives, Chief Scientific Officers, Vice Presidents, Heads, Directors, Prinicple Scientists, Associates, Project Leaders, Specialists, and Managers in the following areas:

Respiratory Physiology & Medicine
Respiratory Pharmacology
Medical Affairs
Inflammatory Disease
Respiratory, Inflammation and Autoimmunity
Pulmonary Disease
Respiratory Therapeutics
Medical & Inhalation Devices
In-Vitro Biology
Inflammation Discovery
Preclinical R&D
Clinical Pharmacology
Clinical Trials
Clinical Science
Global Data Informatics
Business Development
Brand Manager
Respiratory Licensing & Regulation

3M Health Care; AlgiPharma AS; Almirall; Aptar Pharma; ASTRA ZENECA; AstraZeneca; Biopharm Insight; Chiesi Farmaceutici SpA; Glaxosmithkline Biologicals; Glenmark Pharmaceuticals Europe; Hayward Medical Communications; HealthQuest Solutions; Helsinki University Central Hospital; HRG GREECE; Imperial College London; ISTAKLAL Hospital; Janssen R&D UK; Manchester Metropolitan University; Mercy University Hospital; MHRA; Mundipharma International; Mundipharma International Ltd; National COPD Foundation; Novartis Horsham Research Centre; Peamount Healthcare Hospital ; Randox Laboratories Ltd; Sandoz International Gmbh; Teva UK Ltd; University College London; Verona Pharma;

Conference programme

8:30 Registration & Coffee

9:00 Chairman's Opening Remarks

Frank Thielmann

Frank Thielmann, Operational Lead, Inhalation New Solids, Novartis Pharma AG

9:10 From molecule to medicine - formulation development and manufacturing of dry powder inhalation products

Frank Thielmann

Frank Thielmann, Operational Lead, Inhalation New Solids, Novartis Pharma AG

•          Device and formulation systems and their selection
•          Properties of drug substance and product and impact on in-vitro/ vivo performance  
•          Challenges in the manufacturing of DPI systems
•          Future trends in inhaled drug delivery

9:50 Optimising treatment for COPD – new strategies for combination therapy

Ewan Walters

Ewan Walters, Medical Director, Teva UK Ltd

• Are therapies that provide bronchodilation useful in COPD?
• Pros and cons of combination therapies
• Role of real Life Data
• Change in management strategies in UK    

10:30 Morning Coffee

11:00 Triple fixed dose combination therapy in COPD

Geoff Down

Geoff Down, Medical Director, Respiratory Portfolio, Circassia Ltd

• Therapeutic rationale
• Development challenges
• Potential future options

11:40 p38 mitogen-activated protein kinase pathways in asthma and COPD

Pankaj Bhavsar

Pankaj Bhavsar, Research Lecturer, Imperial College London

  • Patients with severe asthma or COPD are resistant to the beneficial therapeutics effects of corticosteroid therapy
  • Heightened p38 MAPK activity is observed in alveolar macrophages (AM), peripheral blood mononuclear cells (PBMC) and airway smooth muscle cells of severe asthma and COPD, and is associated with impaired steroid suppression of cytokine release 
  • A p38 MAPK inhibitor and dexamethasone synergistically suppress induced cytokine release in AM and PBMC of severe asthma or COPD  
  • p38 MAPK inhibitors provide a potential new therapy for the treatment of severe asthma or COPD where reversibility of corticosteroid insensitivity could lead to better control of disease symptoms.
  • 12:10 Networking Lunch

    13:30 Ceramide 1-phosphate, a novel therapeutic agent for treatment of COPD

    Antonio Gomez-Munoz

    Antonio Gomez-Munoz, Professor of Biochemistry and Molecular Biology, University of the Basque Country

    • Ceramide 1-phosphate (C1P) reduces lung inflammation
    • C1P stimulates cell growth, inhibits apoptosis, and promotes cell migration
    • The mechanisms by which C1P blocks inflammatory responses involve inhibition of sphingomyelinase and serine palmitoyl transferase activities, reduction of pro-inflammatory cytokines, and inhibition of NF-kB expression.

    14:10 Asthma-Chronic obstructive pulmonary disease Overlap Syndrome: ACOS or C(H)AOS?

    Konstantinos Kostikas

    Konstantinos Kostikas, Medical Director Respiratory COPD Region Europe, Novartis Pharma
    View Bio

  • Definition and characteristics of a grey-zone syndrome, excluded from current asthma and COPD trials
  • Applying current knowledge to clinical practice
  • Unmet needs and the future of ACOS
  • 14:50 Afternoon Tea

    15:20 Developing clinical trials in pulmonary rehabilitation

    Chetna  Bhatia

    Chetna Bhatia, Respiratory Therapist & Research , HUG

    • Patient selection and recruitment
    • Designing an effective rehabilitation programme
    • Overcoming recruitment and adherence hurdles
    • Prospects in the field

    16:10 Asthma–chronic obstructive pulmonary disease (COPD) overlap syndrome (ACOS)

    Brian Leaker

    Brian Leaker, Medical Director at Respiratory Clinical Trials, The Heart Lung Centre

    • Incidence of ACOS
    • Clinical trials have consistently ignored this condition, as evidenced by strict inclusion and exclusion criteria that exclude either asthma patients from COPD studies or COPD patients from asthma studies, how this is changing in drug development programmes
    • Explaining the phenotype
    • Review of potential pharmacotherapeutic approaches

    16:50 Chairmans Closing Remarks and Close of Day One

    8:30 Registration & Coffee

    9:00 Chairman's Opening Remarks

    Stefano Petruzzelli

    Stefano Petruzzelli, Chief Medical Officer and Director Global Clinical Development, Chiesi Farmaceutici S. P. A.

    9:10 Analysis of COPD biomarkers in sputum at the point-of-care

    Paul Lewis

    Paul Lewis, Chief Scientific Officer, Glyconics

    • Use of infra-red spectroscopy in respiratory clinical diagnostics
    • Determination of sputum biomarkers for COPD and exacerbation
    • Development of a simple hand-held device for biomarker detection
    • Determination of sensitivity and specificity to predict exacerbation using device and biomarkers
    • Evaluation of device in the SPEDIC clinical trial
    • Potential for use of device in primary care to aid COPD management

    9:50 Investigating the role of ectopic lymphoid follicles in respiratory disease

    Matthew Sleeman

    Matthew Sleeman, Senior Director of Biology, Respiratory, Inflammation and Autoimmunity, MedImmune

    • Exploring the role of lung damage and injury in formation of ectopic follicles
    • Evaluation of follicle formation in models of COPD
    • Review the key pathways and mechanisms that contribute to lymphoid follicle formation in COPD and related interstitial lung diseases

    10:30 Morning Coffee

    11:00 Endpoints in COPD trials

    Sanjeeva Dissanayake

    Sanjeeva Dissanayake, Head of Medical Sciences – Respiratory, Mundipharma

    • An overview of endpoints used in COPD trials: pitfalls, limiting risk, and extracting additional value
    • A focus on phase 3 registration studies

    11:40 Understanding COPD and comorbidities

    John Hurst

    John Hurst, Senior Clinical Lecturer, Honorary Consultant, University College London

    • What is the link between comorbidities and disease
    • Current issues with treatments for COPD
    • The use of corticosteroids, do they cause more harm than good?

    12:20 Networking Lunch

    13:20 The ADEPT study "Airways Disease Endotyping for Personalised Therapeutics": Study design, populations and initial learnings

    Philip Silkoff

    Philip Silkoff, Senior Medical Director, Centocor

  • COPD is a heterogeneous disease; surprised?
  •  When assessing biomarkers in COPD, there may be profound impacts of current smoking and also inhaled steroid use.
  •  A deeper level of disease understanding may assist in discovering novel therapies for COPD based on a personalized medicine approach
  • 14:00 Update on the clinical management of exacerbations

    Stefano Petruzzelli

    Stefano Petruzzelli, Chief Medical Officer and Director Global Clinical Development, Chiesi Farmaceutici S. P. A.

    • The course of COPD exacerbations. What are we measuring?
    • Similarities and differences between healthcare resource utilisation definition and EXACT
    • How do exacerbations relate to a range of health outcomes

    14:40 Afternoon Tea

    15:10 A Patients Lifecycle

    Kevin Stirzaker

    Kevin Stirzaker, Head of Security and Compliance, Truphone

  • Denial - Of course I haven't got COPD
  • Acceptance - OK, so I do have COPD
  • Deal with it - No getting away from COPD
  • Realisation - The future with COPD



    15:40 Respiratory research in the UK - the role of the British Lung Foundation

    Noel  Snell

    Noel Snell, Director of Research , British Lung Foundation

    • The current state of UK respiratory research: why is it grossly underfunded compared with therapeutic areas of similar disease burden?
    • Development of a revised research strategy for the BLF in partnership with patients
    • What is the future outlook for respiratory research in the UK?

    16:20 Chairman’s Closing Remarks and Close of Day Two



    Frank Thielmann

    Frank Thielmann

    Operational Lead, Inhalation New Solids, Novartis Pharma AG
    Konstantinos Kostikas

    Konstantinos Kostikas

    Medical Director Respiratory COPD Region Europe, Novartis Pharma
    Matthew Sleeman

    Matthew Sleeman

    Senior Director of Biology, Respiratory, Inflammation and Autoimmunity, MedImmune
    Philip  Silkoff

    Philip Silkoff

    Senior Medical Director, Johnson and Johnson Pharmaceutical Services LLC
    Sanjeeva Dissanayake

    Sanjeeva Dissanayake

    Head of Medical Sciences – Respiratory, Mundipharma

    Antonio Gomez-Munoz

    Professor of Biochemistry and Molecular Biology, University of the Basque Country
    Antonio Gomez-Munoz

    Brian Leaker

    Medical Director at Respiratory Clinical Trials, The Heart Lung Centre
    Brian Leaker

    Chetna Bhatia

    Respiratory Therapist & Research , HUG
    Chetna  Bhatia

    Ewan Walters

    Medical Director, Teva UK Ltd
    Ewan Walters

    Frank Thielmann

    Operational Lead, Inhalation New Solids, Novartis Pharma AG
    Frank Thielmann

    Geoff Down

    Medical Director, Respiratory Portfolio, Circassia Ltd
    Geoff Down

    Graham Clarke

    Head of Respiratory Phase I, Quintlies Ltd.
    Graham Clarke

    Jan-Anders Karlsson

    CEO , Verona Pharma
    Jan-Anders Karlsson

    John Hurst

    Senior Clinical Lecturer, Honorary Consultant, University College London
    John Hurst

    Juan Gispert

    Senior Medical Director and Chair Centre of Excellence, Quintiles
    Juan Gispert

    Kevin Stirzaker

    Head of Security and Compliance, Truphone
    Kevin Stirzaker

    Konstantinos Kostikas

    Medical Director Respiratory COPD Region Europe, Novartis Pharma
    Konstantinos Kostikas

    Dr Konstantinos Kostikas, MD, PhD, FCCP
    Regional Medical Director Respiratory, Region Europe, Novartis Pharma

    I am a Pulmonologist trained in the University of Athens Medical School and the Royal Brompton Hospital, UK. I practiced Respiratory Medicine since 2004 in Academic (University of Thessaly and Atehns Medical Schools, Greece) and private practice settings. I was involved in several posts of the European Respiratory Society (ERS), including the role of Learning Resources Director. My research activities focus on asthma and COPD (biomarkers, phenotyping, comorbidities and exacerbations). I have 110 publications in PubMed since 2002 and several contributions to medical textbooks. I am since January 2015 the Regional Medical Director Respiratory (COPD) Region Europe, Novartis Pharma.

    Matthew Sleeman

    Senior Director of Biology, Respiratory, Inflammation and Autoimmunity, MedImmune
    Matthew Sleeman

    Noel Snell

    Director of Research , British Lung Foundation
    Noel  Snell

    Pankaj Bhavsar

    Research Lecturer, Imperial College London
    Pankaj Bhavsar

    Paul Lewis

    Chief Scientific Officer, Glyconics
    Paul Lewis

    Philip Silkoff

    Senior Medical Director, Johnson and Johnson Pharmaceutical Services LLC
    Philip  Silkoff

    Sanjeeva Dissanayake

    Head of Medical Sciences – Respiratory, Mundipharma
    Sanjeeva Dissanayake

    Stefano Petruzzelli

    Chief Medical Officer and Director Global Clinical Development, Chiesi Farmaceutici S. P. A.
    Stefano Petruzzelli

    Sponsors and Exhibitors

    Official Media Partner



    Improving probability of success in COPD drug development

    Improving probability of success in COPD drug development

    Holiday Inn Regents Park
    21st October 2015
    London, United Kingdom

    An Interview with Quintiles


    COPD 2015 Attendee List


    An interview with Chetna Bhatia, Physical Therapist at University Hospital Geneva


    Sponsors and Exhibitors

    Medicines Evaluation Unit

    Sponsors and Exhibitors

    The Medicines Evaluation Unit is one of the UKs leading contract research organisations, possessing extensive pharmaceutical, scientific and clinical expertise, allied with fast volunteer recruitment within a state of the art hospital-based research facility, enabling MEU to offer clients positive clinical trials solutions. The MEUs core skill area is in respiratory clinical trials, together with early phase exploratory studies, enhanced by the specialist support offered by collaboration with the University Hospital of South Manchester NHS Trust, and its extensive facilities. The MEU has also undergone favourable inspections by the MHRA, and holds MHRA phase 1 accreditation, together with an MHRA MIA (IMP) licence to perform assembly activities.


    Sponsors and Exhibitors

    Quintiles Transnational (NYSE: Q), is a Fortune 500 company and the world’s largest provider of biopharmaceutical development and commercial outsourcing services with a network of more than 32,000 employees conducting business in approximately 100 countries.

    Media Partners

    ONdrugDelivery Magazine

    Official Media Partner

    ONdrugDelivery provides 30,000 readers throughout global pharma/biopharma, with the latest, most pertinent industry information and intelligence about the drug delivery-related ideas, technologies, services and products the sector is developing. Established in 2004, and trusted throughout the industry for its high quality contributions from leading drug delivery experts, ONdrugDelivery is a must for pharma / biotech industry professionals who need to know what’s going on in drug delivery. Subscribe online today to the print or free digital edition: www.ondrugdelivery.com/subscribe.

    BioMed Central - COPD Research and Practice

    Official Media Partner

    BioMed Central is an online STM publisher of more than 270 peer-reviewed open access journals. The portfolio of journals spans all areas of biology, biomedicine and medicine, with many journals publishing content related to pulmonary medicine and allergy research. Examples of such journals include: COPD Research and Practice, Multidisciplinary Respiratory Medicine, Respiratory Research, and Allergy, Asthma & Clinical Immunology. All original research articles published by BioMed Central are made freely accessible online immediately upon publication. Authors publishing with BioMed Central retain copyright of their work, licensing it under the Creative Commons Attribution License which allows articles to be re-used and re-distributed without restriction, as long as the original work is correctly cited. BioMed Central is owned by Springer Science+Business Media, and also hosts the SpringerOpen platform.

    Respiratory Research

    Official Media Partner

    The leading open access respiratory journal, with an Impact Factor of 3.36 and monthly accesses of over 150,000. Publishing on all areas of basic and clinical respiratory medicine, including asthma and COPD.

    BMC Pulmonary Medicine

    Official Media Partner

    An open access, peer-reviewed journal that considers articles on all aspects of the prevention, diagnosis and management of pulmonary and associated disorders, as well as related molecular genetics, pathophysiology, and epidemiology.

    COPD: Journal of Chronic Obstructive Pulmonary Disease

    Official Media Partner

    COPD: Journal of Chronic Obstructive Pulmonary Disease publishes advances in the pathophysiology, diagnosis, management, and control of lung and airway disease and inflammation - providing a unique forum for the discussion, design, and evaluation of more efficient and effective strategies in patient care.

    Media Partners



    Established in October 2003, PharmiWeb Solutions is an energetic, innovative provider of web-based solutions for the pharmaceutical sector, with customers such as AstraZeneca, Roche, Servier Laboratories, and Merck With solutions in three key areas: Online Publishing, e-Business and Mobile Computing, we deliver connectivity – between people and applications – unlocking islands of data and knowledge. We own some of the sector’s most innovative Online Publications: PharmiWeb.com, HospitalPharma.com and Detail-Direct.com. We are actively developing solutions for Mobile Computing platforms. For example, our PharmiTabTM e-pharmacy solution runs real-time patient data and prescribing transactions in a busy hospital environment, on a TabletPC, wireless client/server platform. e-Business solutions range from e-Detailing, to Online Market Research, all designed to increase reach, increase sales, and to reduce administration and costs.

    Technology Networks


    Founded in 2000, Technology Networks is established as the leading news provider for life science and drug discovery professionals. In addition, we provide unique content including webcasts, videos, application notes and posters from recent conferences. Our portfolio now includes around 30 focussed scientific communities, all of which are accessible free of charge within TechnologyNetworks.com



    MedNous is a print publication and website about medical innovation in Europe. It carries exclusive interviews with companies that are at the forefront of medical technology, as well as contributor articles from prominent practitioners. Our mission is to identify significant advances in medicine and to explain how this innovation is being commercialised. In doing so, we talk to venture capitalists about what products and platforms they are supporting. We report on how regulators cope with the accelerating pace of innovation. And we regularly cover the latest developments in the discovery and development of new medical concepts in the area of antibodies, vaccines, small molecules, regenerative medicine and nanomedicines. MedNous combines the English word for medicine with the Greek word for intellect. And those with nous are readers of our publication. Visit our website: www.mednous.com



    PharmaVision offers a consultancy service providing independent pharmaceutical thematic research to the healthcare industry, the investment community and competitive intelligence specialists. We perform due diligence research and provide expert commentary in healthcare. Our reports combine scientific analysis in drug delivery, R&D technologies and pharmaceutical products including patient modelling, product/technology forecasts and market trends evaluation.



    Lab Bulletin


    Lab Bulletin is a free online resource for scientists and laboratory professionals where you can catch up on the latest news for laboratory products and services. You will find an extensive directory of laboratory suppliers and manufacturers enabling you to contact companies quickly and easily to request further information. Lab Bulletin also publishes four free monthly E-Newsletters keeping you up-to-date with all of the latest laboratory products and industry news directly to your inbox. We have dedicated E-Newsletters for Chromatography and Spectroscopy, Microscopy and Image Analysis, weekly Industry News updates and our monthly Lab Bulletin E-Newsletter sent out to over 29,000 readers worldwide. To request your free copy click here

    International Pharmaceutical Industry


    IPI gives you an insight into all areas of Biopharm, Medical, Pharmaceutical and Healthcare. IPI provides a proven supportive means of communication to the Pharmaceutical, Bio Pharmaceutical, Nutraceutical and Medical Devices industry, incorporating the latest in research and technology innovations, regulatory guidelines, marketing and communication strategies.

    Inderscience Publishers


    Inderscience is a dynamic, leading, independent journal publisher. The company disseminates the latest research across the broad fields of science, engineering and technology; management, public and business administration; environment, ecological economics and sustainable development; computing, ICT and internet/web services, and related areas. Inderscience offers over 35 years' experience in publishing and has succeeded in building a substantial collection approaching 400 high-quality peer-reviewed international research journals in both online and print formats. We offer a variety of ways to keep up-to-date with the latest published leading-edge research while our online collection represents a fully-searchable digital archive of around 60,000 articles.

    Contract Biotechnology


    Contract-Biotechnology.com is a web-based platform for laboratory outsourcing solutions. It is an online R&D matching tool that connects Scientifics and service and product providers worldwide. The platform Contract-Biotechnology.com would help you in the process of finding the right partner saving time and money, because with one single and secure application you would be able to receive multiple quotes quickly, keeping your contact information confidential. Contract-Biotechnology.com is the new Collaboration Network Model for Discovery Research and Development. Contract-Biotechnology.com team has extensive experience working for pharmaceuticals, biotechs, universities and academic research institutes and can help you addressing your key gaps.



    Labsave is the leading savings website for Laboratory Equipment and Lab Supplies. We work closely with the top suppliers in the world to bring you the best products at the most competitive prices. We are constantly striving to secure the biggest and most exclusive offers that you won’t find anywhere else! http://www.labsave.com/

    Medical News Today


    Medical News Today is the largest independent medical and health news site on the web - with over 10,000,000 monthly unique users it is ranked number one for medical news on all major search engines. Medical News Today is used by pharmaceutical, biotech and health organizations, advertising agencies, PR companies and vertical ad networks to deliver targeted campaigns to HCPs, patients and caregivers. To find out how Medical News Today can help you to reach the right audience contact peter@medicalnewstoday.com or visit www.medicalnewstoday.com.



    Absave.com is the leading savings website for Antibodies and Immunological Products. Search our extensive database of Antibodies, Kits, Proteins & Peptides, Reagents, etc. to find the best savings!



    Pharmalicensing (www.pharmalicensing.com) is the premier biopharmaceutical Open Innovation resource designed for professionals involved with partnering, licensing and business development worldwide. Actively supporting all forms of partnering and in- and out-licensing activities, Pharmalicensing utilizes the unique online Showcase Profiling & Discover services, as well as its renowned Partnering Search service leveraging its global network of industry experts, to enable companies to identify and engage with appropriate partners around the world. Pharmalicensing is actively utilized by many tens of thousands of industry professionals each month. Pharmalicensing is a division of Cognis Group, Inc.

    Drug Discovery Today


    Drug Discovery Today covers the whole of the preclinical drug discovery process. The reviews are cutting edge, written by experts in their respective fields and cover all aspects of drug discovery from genomic and proteomic approaches, computational drug design, medicinal chemistry and the translation of these sciences to therapies.



    PharmaCircle is an innovative knowledge management company serving the current and future global leaders in the Pharmaceutical and Biotechnology related industries. PharmaCircle is a one stop information and analysis source for pipeline, products, clinical trials, drug delivery technologies, deals and acquisitions, company financials, venture capital investments, product sales, pharmaceutical services, news, patents and more….



    pharmaphorum drives innovation within the pharmaceutical industry, by bringing healthcare together through a suite of media services that help produce and disseminate thought leadership, combined with an online platform for communicating messages to a global audience.Visit www.pharmaphorum.com

    Swiss Biotech Association


    The Swiss Biotech Association (SBA) is the national industry association for biotechnology, including pharmaceuticals, diagnostics, agriculture, food, cosmetics, environmental biotechnology, and specialty chemicals. Members are companies active in modern biotechnology, such as R&D, Production, Marketing and Sales, Finance, Services and Consulting. SBA provides a networking platform for Life Science clusters, academic and federal institutions the like. Founded in March 1998, the Association grows steadily.

    KONGPOSH Publications


    KONGPOSH Publications is one of India’s leading Pharma Publishers. The Pharma Review® is a bi-monthly article based journal covering various fields of pharmacy. Participation and distribution in over 30 Expos & Conferences worldwide each year. It is widely read by decision makers, middle management and the academia. Also available in E-book format. Other publications : Indian Pharma Reference Guide (Annual) – Names and address of Pharmaceuticals, Bulk Drugs, Machinery’s & Instrumentation, AYUSH Manufacturers; and much more; High Performance Thin Layer Chromatography; Elements of Pharmacovigilance; Regulation of Clinical Trials; AYUSH (CD); NDDS/AMD (CD)

    Taylor & Francis Group


    As one of the world’s leading publishers of scholarly journals, books, eBooks, reference works, and databases, Taylor & Francis Group partners with researchers, scholarly societies, universities, and libraries worldwide to bring knowledge to life.

    Int. J. of Biotechnology


    IJBT provides an international forum and refereed authoritative source of information in the field of Biotechnology and Biotechnics, with emphasis on management and economics, as well as the political and social issues. It aims to disseminate knowledge, provide a learned reference in the field, and establish channels of communication between academic and research experts, policy makers and executives in industry, commerce and investment institutions.



    GBI is an information, applications, and services company focused on the healthcare industry. Leveraging data from across the healthcare value chain, GBI creates web and mobile applications that enable individuals and organizations to make better decisions and communicate more effectively.

    Antibodies Online


    antibodies-online.com facilitates researchers to find the appropriate antibodies for their respective research project. As an independent and multi-vendor marketplace for research antibodies and thanks to the cooperation with more than 130 different manufacturers, a large selection of Antibodies (over 700,000), ELISA Kits (over 130,000), Secondary Antibodies (17,000), Proteins (130,000), Peptides and Isotype Controls is available. By supporting the Independent Validation Initiative and the Resource Identification Initiative, antibodies-online.com also addresses the important topics of transparent product quality and scientific reproducibility. In addition scientists receive news and detailed information about the individual antibodies from databases such as the PubMed and others.

    evvnt Ltd


    evvnt enables people all over the world to fill their events utilising the most effective event listing sites on the web. Every minute, with little more than a click, more events and conferences appear in listings, in search engines and on mobile - discoverable by both category and location. With next to no effort customers of evvnt get better attendance, while consumers find events they previously had no idea existed. To date customers in 70 countries worldwide have submitted over 500,000 thousand event listings, created over 300,000 live links, and generated 1 million clicks to ticketing and registration pages. Learn more at www.evvnt.com

    Select Science


    SelectScience is an independent, online information resource for the worldwide scientific community, and the home of trusted information for laboratory scientists. Discover impartial, expert opinion and trusted reviews about latest laboratory equipment and techniques; plus videos, application notes and science news from around the world. Become a member for free today.



    PMR (www.pmrcorporate.com) is a British-American company providing market information, advice and services to international businesses interested in Central and Eastern European countries as well as other emerging markets. PMR's key areas of operation include business publications (through PMR Publications), consultancy (through PMR Consulting) and market research (through PMR Research ). Being present on the market since 1995, offering high international standards in projects and publications, as well as providing one of the most frequently visited and top-ranked websites, PMR is one of the largest companies of its type in the region.



    Gate2Biotech is a portal that unites biotechnological community in Central Europe. It covers all the news in the field of biotechnology. Thanks to the the portal the companies engaged in the field can easily search for research institutions and other partners to solve technical problems they are facing and here they can also present their services offer to potential partners from the Czech Republic and abroad. Gate2Biotech portal serves as a bridge connecting scientific and commercial sector. It incorporates offices and support organizations dedicated to promoting transfer of innovative technologies into a unified communication platform of Czech and international biotechnologies. As a mediator of information it draws attention to biotechnologies and support of their application and transfer into practice. It also functions as a tool for encouraging non-professionals (especially scientists and students) towards innovative business or applied research.



    Biosave.com brings together the best Life Science promotions, product releases, featured products, publications, videos and events from 100’s of leading Life Science suppliers. Updated 24 hours a day, Biosave is constantly uploading special promotions and exciting product news that you won’t find anywhere else. Our goal is to provide our users with the most exclusive product information to help reach that all important purchasing decision.

    Holiday Inn Regents Park

    Carburton Street
    London W1W 5EE
    United Kingdom

    Holiday Inn Regents Park

    Choose the well-connected Holiday Inn London-Regent's Park hotel, with a superb central London location and speedy transport links. Holiday Inn London-Regent's Park is in a leafy and cosmopolitan area of central London, a 10-minute walk from bustling Oxford Street. Leave your car in our NCP managed underground car park, and explore London by Tube. Great Portland Street Tube station is 25 metres from the hotel, from where you can reach the City and Canary Wharf in 30 minutes, and London Heathrow Airport in 45 minutes.

    Wireless Internet is available throughout the hotel, and you can invite up to 300 people to events at the Academy Conference Centre, with an IT technician and break-out zones. Holiday Inn London-Regent's Park is a 10-minute walk from Santander's offices and businesses in the BT Tower. Stroll 5 minutes to Regent's Park, where you'll find London Zoo and pretty Primrose Hill. We're a 10-minute walk from Bond Street boutiques and 20 minutes from Buckingham Palace and cruises on the River Thames.

    Ask our Concierge to plan your day out and book West End theatre tickets. Room Service is available 24 hours at Holiday Inn London-Regent's Park, or dine in the vibrant Junction Restaurant. Our Junction Bar has a menu of light bites, and a hot breakfast buffet is served daily.



    speaker image






    CPD stands for Continuing Professional Development’. It is essentially a philosophy, which maintains that in order to be effective, learning should be organised and structured. The most common definition is:

    ‘A commitment to structured skills and knowledge enhancement for Personal or Professional competence’

    CPD is a common requirement of individual membership with professional bodies and Institutes. Increasingly, employers also expect their staff to undertake regular CPD activities.

    Undertaken over a period of time, CPD ensures that educational qualifications do not become obsolete, and allows for best practice and professional standards to be upheld.

    CPD can be undertaken through a variety of learning activities including instructor led training courses, seminars and conferences, e:learning modules or structured reading.


    There are approximately 470 institutes in the UK across all industry sectors, with a collective membership of circa 4 million professionals, and they all expect their members to undertake CPD.

    For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked to a licence to practice, for others it’s obligatory. By ensuring that their members undertake CPD, the professional bodies seek to ensure that professional standards, legislative awareness and ethical practices are maintained.

    CPD Schemes often run over the period of a year and the institutes generally provide online tools for their members to record and reflect on their CPD activities.


    Professional bodies and Institutes CPD schemes are either structured as ‘Input’ or ‘Output’ based.

    ‘Input’ based schemes list a precise number of CPD hours that individuals must achieve within a given time period. These schemes can also use different ‘currencies’ such as points, merits, units or credits, where an individual must accumulate the number required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of learning.

    ‘Output’ based schemes are learner centred. They require individuals to set learning goals that align to professional competencies, or personal development objectives. These schemes also list different ways to achieve the learning goals e.g. training courses, seminars or e:learning, which enables an individual to complete their CPD through their preferred mode of learning.

    The majority of Input and Output based schemes actively encourage individuals to seek appropriate CPD activities independently.

    As a formal provider of CPD certified activities, SMI Group can provide an indication of the learning benefit gained and the typical completion. However, it is ultimately the responsibility of the delegate to evaluate their learning, and record it correctly in line with their professional body’s or employers requirements.


    Increasingly, international and emerging markets are ‘professionalising’ their workforces and looking to the UK to benchmark educational standards. The undertaking of CPD is now increasingly expected of any individual employed within today’s global marketplace.

    CPD Certificates

    We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email events@smi-online.co.uk

    Event Title


    Read More

    I would like to speak at an event

    I would like to attend an event

    I would like to sponsor/exhibit at an event


    Sign up
    Forgotten Password?

    Contact SMi GROUP LTD

    UK Office
    Opening Hours: 9.00 - 17.30 (local time)
    SMi Group Ltd, 1 Westminster Bridge Road, London, SE1 7XW, United Kingdom
    Tel: +44 (0) 20 7827 6000 Fax: +44 (0) 20 7827 6001
    Website: http://www.smi-online.co.uk Email: events@smi-online.co.uk
    Registered in England No: 3779287 VAT No: GB 976 2951 71

    Forgotten Password

    Please enter the email address you registered with. We will email you a new password.

    Thank you for visiting our event

    If you would like to receive further information about our events, please fill out the information below.

    By ticking above you are consenting to receive information by email from SMi.
    Full details of our privacy policy can be found here https://www.smi-online.co.uk/privacy-legals/privacy-policy/.
    Should you wish to update your contact preferences at any time you can contact us at data@smi-online.co.uk.
    Should you wish to be removed from any future mailing lists please click on the following link http://www.smi-online.co.uk/opt-out